GEN-MKT-18-7897-A
Jan 13, 2025 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments
Read time: 2 minutes
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Working for a contract research organization and more recently for SCIEX has provided an interesting perspective on trends the market experiences that affect many of us.
Outsourcing
It has been my experience that advancements in technology, particularly in mass spectrometry, have significantly transformed the capabilities and roles of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) in the drug development life cycle. High-resolution mass spectrometry (HRMS) has revolutionized the characterization of complex molecules, enabling precise identification of potential drug candidates and a deeper understanding of their mechanisms of action. Techniques like tandem mass spectrometry (MS/MS) and advanced fragmentation methods such as Electron-Activated Dissociation (EAD) from SCIEX allow for detailed structural elucidation and quantitation of biomolecules, facilitating the development of more targeted and effective therapies.
Artificial intelligence and machine learning
Integrating artificial intelligence (AI) and machine learning (ML) algorithms with mass spectrometry data enhances the potential of CDMOs and CROs by providing predictive insights and optimization strategies for drug discovery and manufacturing processes, improving efficiency and decision-making.
Advanced techniques like native mass spectrometry allow the study of biomolecules in their natural state, aiding research on protein complexes and interactions critical for biologics and personalized medicine. As technology continues to evolve, mass spectrometry will further enhance the efficiency, accuracy, and scope of services offered by CDMOs and CROs, driving innovation in drug development, and leading to the discovery of novel new medicines.
Biosecure Act
Looking forward I expect, the Biosecure Act will undoubtedly complicate biopharmaceutical business, especially in Asia, and this shift is likely to reshape the global biotech landscape. U.S. firms will face more hurdles during collaborations, particularly around gene-editing and sensitive pathogen research. Tightening biosecurity regulations may cause U.S. companies to seek research partners and suppliers based in regions that align better with these new standards, meaning new places may be seen as attractive hubs for innovation, partnerships, and investments. I expect we’ll see a more diversified global distribution of biotech work.
For more information about how SCIEX can support you please visit our website, here>
Thanks to Starbucks, who launched the pumpkin spice latte in 2003 (yes, over 20 years ago), the spice mixture became a global phenomenon, loved and disliked at the same time.
Customer Experience Day (CX Day) is a special occasion for SCIEX, celebrated every first Tuesday in October. It’s a day dedicated to recognizing the incredible value of our customers and the relentless dedication of our associates who strive to make every interaction meaningful. At SCIEX, our commitment to customer experience is woven into the fabric of everything we do. From providing cutting-edge solutions to offering unwavering support, we aim to build lasting relationships and exceed expectations. Join us as we delve into the insights from our leaders on what customer experience means to SCIEX and how it shapes our journey.
Posted by
You must be logged in to post a comment.
Share this post with your network